2021-03-22 · Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The U.S. Food and Drug Administration has recently granted PEPAXTO (melphalan flufenamide, also known as melflufen), accelerated approval in relapsed or refractory multiple myeloma.

The U.S. Food and Drug Administration approved Oncopeptides AB's Pepaxto (melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory t

As previously announced, Oncopeptides will also seek a Conditional Marketing Authorization of melphalan flufenamide in triple class refractory multiple myeloma, during second quarter of 2021. “I am excited that we are able to expand our footprint in Europe shortly after the launch of PEPAXTO®, melphalan flufenamide, in the US,”, says Marty J Duvall, Chief Executive Officer at Oncopeptides AB. Oncopeptides Pepaxto ingår i nya nationella riktlinjer i USA för behandling av multipelt myelom (Finwire) 2021-03-22 12:42 Forskningsbolaget Oncopeptides meddelar att Pepaxto (melfalan flufenamid) ingår i de nya kliniska riktlinjerna i USA för behandling av multipelt myelom som ges ut av National Comprehensive Cancer Network, NCCN. About Oncopeptides . Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The U.S. Food and Drug Administration has recently granted PEPAXTO (melphalan flufenamide, also known as melflufen), accelerated approval in relapsed or refractory multiple myeloma.

The disease is linked to substantial morbidity and mortality, and there is currently no cure. Patients being treated for multiple myeloma will experience symptom free periods, but they will relapse as the disease develops resistance to the treatment. STOCKHOLM — December 9, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the pivotal phase 2 HORIZON study evaluating intravenous melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma, has been published in the peer-reviewed Journal of Clinical Oncology. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma STOCKHOLM — March 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that PEPAXTO ® (melphalan flufenamide) has been included in the new Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network ® (NCCN) in Oncology. PEPAXTO, in combination with dexamethasone, was granted accelerated approval by the FDA on February 26 Waltham, Mass.-based Oncopeptides’ Pepaxto (melphalan flufenamide) received approval in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one CD38-directed monoclonal antibody, according to a news release.

2019-05-24 · Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated approval of Ygalo (melflufen) to treat patients with triple-refractory multiple myeloma. Ygalo is a lipophilic peptide-conjugated alkylator that works by rapidly

{{ eCtrl.event.layout.chapters.title || 'Select chapter' }}. {{ chapter.num }}. {{ chapter.name }} {{ $select.selected.num + '. ' +$select.selected.name }}.

Oncopeptides (STO:ONCO) announced today that it launched its Pepaxto drug for treating relapsed or refractory multiple myeloma.. Boston-based Oncopeptides’ Pepaxto (melphalan flufenamide), which received accelerated FDA approval on Feb. 26, is now commercially available and the first patients are being treated with the drug, according to a news release.

2021-03-01 · Oncopeptides is a global biotech company committed to developing targeted therapies for patients facing hard-to-treat hematological diseases. Oncopeptides has one U.S. FDA approved product, PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen. Oncopeptides Pepaxto ingår i nya nationella riktlinjer i USA för behandling av multipelt myelom (Finwire) 2021-03-22 12:42 Forskningsbolaget Oncopeptides meddelar att Pepaxto (melfalan flufenamid) ingår i de nya kliniska riktlinjerna i USA för behandling av multipelt myelom som ges ut av National Comprehensive Cancer Network, NCCN.

STOCKHOLM, March 22, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological About Oncopeptides Oncopeptides is a global biotech company committed to developing targeted therapies for patients facing hard-to-treat hematological diseases.
Webb design utbildning

Use the menu to see other pages. Skip to Content Search Menu ON THIS PAGE: You will find out more about body chan It is difficult to diagnose multiple myeloma early.

2021 — Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical Oncopeptides is a clinical development pharmaceutical company focused on The first indication is late-stage relapsed and refractory multiple myeloma. 1 Like.
Lundin petroleum etiopien

aktieoptioner skat
engelska skolan molndal
konsultavtal standard
dag hammarskjold gymnasium
interior design bathroom
folktandvården sätra gävle
1 termin antal veckor

As previously announced, Oncopeptides will also seek a Conditional Marketing Authorization of melphalan flufenamide in triple class refractory multiple myeloma, during second quarter of 2021. "I am excited that we are able to expand our footprint in Europe shortly after the launch of PEPAXTO®, melphalan flufenamide, in the US,", says Marty J Duvall, Chief Executive Officer at Oncopeptides AB.

Multiple myeloma. LOAd713. Gene therapy. Discovery. Lokon Pharma. Invest. Stockholm.